Hospital
Community Medical Center INC
Community Medical Center INC was paid $88.25M by Medicaid between Jan 2018 and Dec 2024, across 353 billing codes. Its largest line is G0378, Hospital observation service, per hour — 19% of everything it billed.
33Billing provider infoCOMMUNITY MEDICAL CENTER INC
TOMS RIVER, NJ 08755
TOMS RIVER, NJ 08755
33aNPI1013010917assigned 09/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$88.25M
24GClaims1,374,109
24DCodes billed353
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#21 of 93
Median peer was paid$30.60M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 174,308 | $13.30M | |
| 2019 | 182,175 | $12.96M | |
| 2020 | 152,165 | $9.85M | |
| 2021 | 194,442 | $12.95M | |
| 2022 | 253,412 | $14.03M | |
| 2023 | 237,885 | $13.72M | |
| 2024incomplete | 179,722 | $11.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 19% | 23,595 | 19,305 | $16.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 32,044 | 29,209 | $13.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 35,811 | 33,514 | $13.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 38,934 | 33,771 | $11.79M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.9% | 4,295 | 4,101 | $4.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 10,234 | 9,600 | $2.47M |
| 80053 | Comprehensive metabolic panel | 2.0% | 80,247 | 62,776 | $1.76M |
| 93017 | 1.3% | 1,950 | 1,849 | $1.18M | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 3,381 | 1,886 | $1.14M |
| OP250 | 1.3% | 99,658 | 50,766 | $1.12M | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 25,263 | 6,437 | $1.06M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 1,594 | 1,507 | $889K |
341 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,849 | $786K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,643 | $759K |
| 96367 | <1% | 2,568 | $689K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,313 | $642K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 6,150 | $608K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,812 | $580K |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,888 | $564K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 74,990 | $506K |
| 95800 | <1% | 542 | $488K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,331 | $473K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,790 | $389K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,295 | $348K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,492 | $307K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 18,395 | $305K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,352 | $302K |
| 76830 | Ultrasound, transvaginal | <1% | 2,572 | $299K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 380 | $296K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,341 | $287K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 10,384 | $274K |
| 93970 | <1% | 1,488 | $265K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,119 | $264K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,802 | $244K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,048 | $242K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,371 | $235K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,388 | $221K |
| 76642 | <1% | 1,791 | $215K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,860 | $212K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,940 | $202K |
| 73564 | <1% | 3,166 | $197K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,796 | $189K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,393 | $187K |
| OP710 | <1% | 6,701 | $185K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,861 | $170K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,197 | $166K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,852 | $162K |
| 93971 | <1% | 1,802 | $160K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,030 | $152K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,622 | $150K |
| A9270 | Non-covered item or service | <1% | 23,816 | $147K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,378 | $144K |
| 73630 | <1% | 3,031 | $138K | |
| 73030 | <1% | 2,435 | $122K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,594 | $120K |
| 72110 | <1% | 1,430 | $119K | |
| OP272 | <1% | 8,577 | $119K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,989 | $118K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,016 | $118K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,524 | $117K |
| 82962 | <1% | 12,736 | $116K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,747 | $115K |
| 81001 | <1% | 26,230 | $110K | |
| 73130 | <1% | 2,399 | $109K | |
| 71250 | <1% | 701 | $108K | |
| OP258 | <1% | 37,459 | $106K | |
| 97161 | <1% | 2,043 | $99K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,904 | $99K |
| OP370 | <1% | 6,078 | $96K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 208 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,667 | $93K |
| 77066 | Tomosynthesis, mammo | <1% | 655 | $92K |
| 80061 | Lipid panel | <1% | 5,425 | $90K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 588 | $89K |
| 84484 | <1% | 19,304 | $88K | |
| 73610 | <1% | 2,737 | $87K | |
| 85610 | <1% | 16,221 | $87K | |
| 77065 | Tomosynthesis, mammo | <1% | 943 | $84K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,776 | $82K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,329 | $81K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 2,443 | $79K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 700 | $79K |
| 96415 | <1% | 305 | $77K | |
| 83735 | <1% | 11,778 | $77K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,328 | $71K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,511 | $70K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,697 | $70K |
| 77080 | <1% | 744 | $69K | |
| 85027 | <1% | 18,008 | $67K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 715 | $67K |
| 96376 | <1% | 6,038 | $63K | |
| 85730 | <1% | 11,887 | $62K | |
| 86900 | <1% | 7,800 | $60K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,362 | $58K |
| 73110 | <1% | 1,683 | $58K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,555 | $55K |
| 97162 | <1% | 2,189 | $54K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 89 | $54K |
| 87040 | <1% | 3,992 | $52K | |
| 76536 | <1% | 422 | $52K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 317 | $52K |
| 76775 | <1% | 668 | $51K | |
| 86140 | <1% | 4,455 | $48K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,405 | $48K |
| 87081 | <1% | 3,497 | $47K | |
| 86850 | <1% | 7,455 | $46K | |
| C1776 | Joint device (implantable) | <1% | 15 | $46K |
| 77336 | <1% | 304 | $45K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 600 | $44K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,419 | $43K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 242 | $42K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,594 | $41K |
| 83880 | <1% | 3,679 | $41K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 19 | $41K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 702 | $39K |
| 81003 | <1% | 7,817 | $39K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,083 | $36K |
| 84100 | <1% | 4,964 | $35K | |
| 83690 | <1% | 14,799 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 935 | $33K |
| 85651 | <1% | 3,619 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,870 | $33K |
| 73502 | <1% | 1,486 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,986 | $31K |
| 95811 | <1% | 16 | $29K | |
| 73590 | <1% | 969 | $28K | |
| 76801 | <1% | 305 | $27K | |
| 86901 | <1% | 7,874 | $27K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 832 | $26K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,352 | $26K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,562 | $24K |
| 85007 | <1% | 4,933 | $24K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,103 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,039 | $23K |
| 81025 | <1% | 4,851 | $23K | |
| 97014 | <1% | 1,165 | $23K | |
| 80329 | <1% | 1,432 | $22K | |
| 74018 | <1% | 733 | $22K | |
| 70486 | <1% | 484 | $22K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,815 | $22K |
| 83605 | <1% | 3,688 | $21K | |
| 80320 | <1% | 8,167 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,348 | $21K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,796 | $21K |
| 80164 | <1% | 1,486 | $20K | |
| 96417 | <1% | 109 | $20K | |
| 93458 | <1% | 12 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,887 | $20K |
| 80076 | <1% | 818 | $20K | |
| 84702 | <1% | 3,679 | $19K | |
| 93975 | <1% | 179 | $19K | |
| 76937 | <1% | 88 | $18K | |
| 84439 | <1% | 2,048 | $18K | |
| 82542 | <1% | 1,351 | $17K | |
| 87070 | <1% | 1,200 | $17K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 474 | $17K |
| 73700 | <1% | 118 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,108 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,802 | $16K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,671 | $16K |
| 72050 | <1% | 154 | $15K | |
| 12001 | <1% | 1,020 | $15K | |
| 87088 | <1% | 3,024 | $14K | |
| C1769 | Guide wire | <1% | 1,328 | $14K |
| 82550 | <1% | 2,399 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,472 | $12K |
| 73080 | <1% | 551 | $12K | |
| 71271 | <1% | 69 | $12K | |
| 90715 | <1% | 2,381 | $12K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 640 | $12K |
| 74021 | <1% | 273 | $11K | |
| 87186 | <1% | 1,970 | $11K | |
| 29125 | <1% | 1,112 | $11K | |
| 73140 | <1% | 317 | $11K | |
| 77334 | <1% | 22 | $11K | |
| 73090 | <1% | 476 | $10K | |
| 82607 | <1% | 1,094 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,905 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 778 | $9K |
| 29515 | <1% | 986 | $9K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 564 | $9K |
| 12011 | <1% | 499 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,788 | $9K |
| 84134 | <1% | 740 | $9K | |
| 97116 | <1% | 1,033 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,039 | $9K |
| 80179 | <1% | 4,068 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 42 | $8K |
| 20610 | <1% | 15 | $8K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 910 | $8K |
| 76870 | <1% | 115 | $8K | |
| 0002A | <1% | 219 | $7K | |
| 97035 | <1% | 487 | $7K | |
| 76641 | <1% | 53 | $7K | |
| 84478 | <1% | 236 | $7K | |
| 82248 | <1% | 1,185 | $7K | |
| 0001A | <1% | 209 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 338 | $6K |
| J1815 | Injection, insulin, per 5 units | <1% | 406 | $6K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 455 | $6K |
| 11043 | <1% | 64 | $6K | |
| 87077 | <1% | 1,418 | $6K | |
| 85378 | <1% | 2,663 | $6K | |
| 80143 | <1% | 1,709 | $6K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 283 | $6K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 283 | $6K |
| 85008 | <1% | 1,555 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,248 | $6K |
| 10060 | <1% | 155 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,893 | $6K |
| 77290 | <1% | 13 | $5K | |
| 88304 | <1% | 438 | $5K | |
| 76770 | <1% | 58 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,963 | $5K |
| 71100 | <1% | 98 | $5K | |
| 97166 | <1% | 556 | $5K | |
| 84703 | <1% | 371 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 443 | $4K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 644 | $4K |
| 92523 | <1% | 74 | $4K | |
| 84436 | <1% | 764 | $4K | |
| OP255 | <1% | 1,122 | $4K | |
| 82728 | <1% | 455 | $4K | |
| 87205 | <1% | 1,340 | $4K | |
| 87486 | <1% | 439 | $4K | |
| 93880 | <1% | 13 | $4K | |
| OP278 | <1% | 15 | $4K | |
| 72170 | <1% | 245 | $4K | |
| 74174 | <1% | 26 | $3K | |
| 36430 | <1% | 15 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,460 | $3K |
| 12002 | <1% | 142 | $3K | |
| 87581 | <1% | 439 | $3K | |
| 87147 | <1% | 197 | $3K | |
| 82746 | <1% | 248 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 33 | $3K |
| 72100 | <1% | 102 | $3K | |
| 88342 | <1% | 375 | $3K | |
| 84481 | <1% | 110 | $3K | |
| 29505 | <1% | 264 | $3K | |
| 70544 | <1% | 24 | $3K | |
| 86920 | <1% | 149 | $3K | |
| 80202 | <1% | 95 | $3K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 113 | $3K |
| 83540 | <1% | 620 | $2K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 67 | $2K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 67 | $2K |
| 93925 | <1% | 17 | $2K | |
| 87631 | <1% | 61 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 28 | $2K |
| 93308 | <1% | 46 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 427 | $2K |
| 72131 | <1% | 62 | $2K | |
| 82805 | <1% | 302 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 913 | $2K |
| 85055 | <1% | 412 | $2K | |
| 77280 | <1% | 14 | $2K | |
| 85379 | <1% | 672 | $2K | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 28 | $2K |
| 73552 | <1% | 189 | $2K | |
| 83550 | <1% | 373 | $2K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 14 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $1K |
| 72070 | <1% | 37 | $1K | |
| OP637 | <1% | 1,846 | $1K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 749 | $1K |
| 82570 | <1% | 374 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $1K |
| 73060 | <1% | 68 | $1K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 118 | $995.72 |
| 29130 | <1% | 78 | $942.40 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 213 | $933.50 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 266 | $897.13 |
| 92522 | <1% | 14 | $876.00 | |
| 73070 | <1% | 43 | $845.03 | |
| 82150 | <1% | 72 | $842.94 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 14 | $825.59 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 224 | $747.81 |
| 0011A | <1% | 21 | $744.96 | |
| 0012A | <1% | 21 | $744.96 | |
| 15853 | <1% | 26 | $698.16 | |
| 82043 | <1% | 195 | $679.22 | |
| 82553 | <1% | 59 | $603.50 | |
| 83615 | <1% | 358 | $570.12 | |
| 0004A | <1% | 16 | $552.34 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13 | $541.95 |
| 84153 | <1% | 42 | $523.21 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 15 | $501.60 |
| 76882 | <1% | 17 | $499.61 | |
| 77002 | <1% | 30 | $478.65 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 61 | $470.94 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 837 | $463.66 |
| 70496 | <1% | 15 | $449.23 | |
| 70498 | <1% | 16 | $444.30 | |
| 0054A | <1% | 12 | $440.00 | |
| 88307 | <1% | 15 | $413.65 | |
| 82140 | <1% | 113 | $346.82 | |
| 83970 | <1% | 13 | $346.77 | |
| 85652 | <1% | 461 | $338.36 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 28 | $335.69 |
| 88312 | <1% | 15 | $296.26 | |
| 84156 | <1% | 75 | $261.79 | |
| 84520 | <1% | 516 | $241.99 | |
| 85014 | <1% | 116 | $237.75 | |
| 0031A | <1% | 39 | $233.70 | |
| 82010 | <1% | 40 | $232.13 | |
| 84480 | <1% | 40 | $227.58 | |
| 82565 | <1% | 40 | $220.57 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 308 | $219.06 |
| 84550 | <1% | 58 | $192.32 | |
| 88142 | <1% | 12 | $165.42 | |
| 85018 | <1% | 115 | $128.21 | |
| 97165 | <1% | 16 | $124.12 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $116.78 |
| 80177 | <1% | 55 | $106.87 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 140 | $91.02 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 308 | $77.12 |
| 36600 | <1% | 31 | $75.95 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 392 | $74.22 |
| 87075 | <1% | 111 | $69.61 | |
| 88300 | <1% | 14 | $66.54 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 152 | $62.74 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 25 | $60.47 |
| 87493 | <1% | 14 | $58.46 | |
| 82803 | <1% | 28 | $52.31 | |
| 84145 | <1% | 13 | $47.24 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 82 | $42.81 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 90 | $30.49 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 18 | $28.74 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 15 | $7.64 |
| 82274 | <1% | 12 | $7.40 | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 113 | $7.00 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 29 | $6.44 |
| OP270 | <1% | 32 | $5.34 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 30 | $5.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 13 | $3.65 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 17 | $3.20 |
| 86308 | <1% | 14 | $3.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 40 | $2.59 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 195 | $2.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 12 | $2.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 12 | $2.00 |
| 80178 | <1% | 20 | $1.00 | |
| 91300 | <1% | 107 | $1.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 12 | $1.00 |
| 91301 | <1% | 18 | $0.01 | |
| 84132 | 0% | 163 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 50 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 13 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 12 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 27 | $0.00 |
| 29105 | 0% | 12 | $0.00 | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAJART, AARON (CEO)
Parent organizationRWJ BARNABAS HEALTH INC